First patients test new pill targeting tough stomach cancers
NCT ID NCT06056024
Summary
This was a first-in-human study to find a safe and tolerable dose of a new oral drug, BI 3706674, for adults with advanced stomach or esophageal cancer that had stopped responding to other treatments. The trial tested different dose levels to see how the drug was processed by the body and whether it could shrink tumors. It specifically enrolled patients whose cancer had a certain genetic feature (KRAS wild type amplified).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, KRAS MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ajou University Hospital
Suwon, 16499, South Korea
-
Asan Medical Center
Seoul, 05505, South Korea
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic-Arizona
Phoenix, Arizona, 85054, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
NCKUH
Tainan, 704, Taiwan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Samsung Medical Center
Seoul, 135-710, South Korea
-
Seoul National University Bundang Hospital
Seongnam, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
The Catholic University of Korea, Seoul St.Mary's Hospital
Seoul, 137-701, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Yale Cancer Center
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.